Inhaled Fentanyl Citrate & Dyspnea

This study has been completed.
Information provided by (Responsible Party):
Dennis Jensen, Ph.D., McGill University Identifier:
First received: May 7, 2013
Last updated: August 24, 2015
Last verified: August 2015
"Dyspnea" refers to the awareness of breathing discomfort that is typically experienced during exercise in health and disease. In various participant populations, dyspnea is a predictor of disability and death; and contributes to exercise intolerance and an adverse health-related quality-of-life. It follows that alleviating dyspnea and improving exercise tolerance are among the principal goals of disease management. Nevertheless, the effective management of dyspnea and activity-limitation remains an elusive goal for many healthcare providers and current strategies aimed at reversing the underlying chronic disease are only partially successful in this regard. Thus, research aimed at identifying dyspnea-specific medications to complement existing therapies for the management of exertional symptoms is timely and clinically relevant. The purpose of this study is to test the hypothesis that single-dose inhalation of fentanyl citrate (a mu-opioid receptor antagonist) will improve the perception of dyspnea during strenuous exercise in healthy, young men in the presence of an external thoracic restriction. To this end, the investigators plan compare the effects of inhaled 0.9% saline placebo and inhaled fentanyl citrate (250 mcg) on detailed assessments of neural respiratory drive (diaphragm EMG), ventilation, breathing pattern, dynamic operating lung volumes, contractile respiratory muscle function, cardio-metabolic function and dyspnea (sensory intensity and affective responses) during symptom-limited, high-intensity, constant-work-rate cycle exercise testing with and without external thoracic restriction in healthy, men aged 20-40 years.

Condition Intervention Phase
Drug: Fentanyl Citrate
Other: CWS
Drug: Placebo
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Inhaled Fentanyl Citrate on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction

Resource links provided by NLM:

Further study details as provided by McGill University:

Primary Outcome Measures:
  • Sensory intensity (Borg 0-10 scale) ratings of dyspnea at isotime [ Time Frame: Participants will be followed until all study visits are completed, an expected average of 3 weeks ] [ Designated as safety issue: No ]

Enrollment: 14
Study Start Date: June 2013
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CWS+Fentanyl Citrate (250 mcg)
Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
Drug: Fentanyl Citrate Other: CWS
Chest wall strapping to reduce vital capacity by 20% of its baseline value
Other Name: chest wall strapping
Placebo Comparator: CWS+0.9% saline placebo
Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
Other: CWS
Chest wall strapping to reduce vital capacity by 20% of its baseline value
Other Name: chest wall strapping
Drug: Placebo
0.9% saline
Active Comparator: No CWS+Fentanyl Citrate (250 mcg)
No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
Drug: Fentanyl Citrate
Placebo Comparator: No CWS+0.9% saline placebo
No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
Drug: Placebo
0.9% saline


Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male
  • Aged 20-40 years
  • FEV1 ≥80% predicted
  • FEV1/FVC >70%

Exclusion Criteria:

  • Current or ex-smoker
  • Body Mass Index <18.5 or >30 kg/m2
  • History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction
  • Taking doctor prescribed medications
  • History of using pain-relieving (opioid) and/or anti-depressant medications in the previous 6 weeks
  • Allergy to latex
  • Allergy to lidocaine or its "caine" derivatives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01853449

Canada, Quebec
Montreal Chest Institute; McGill University Health Center & McGill University
Montreal, Quebec, Canada, H2X 2P4
Sponsors and Collaborators
McGill University
Principal Investigator: Dennis Jensen, Ph.D. McGill University
  More Information

Additional Information:
No publications provided

Responsible Party: Dennis Jensen, Ph.D., Assistant Professor, McGill University Identifier: NCT01853449     History of Changes
Other Study ID Numbers: A02-M16-13B Fentanyl
Study First Received: May 7, 2013
Last Updated: August 24, 2015
Health Authority: Canada: Ethics Review Committee

Keywords provided by McGill University:
Fentanyl Citrate

Additional relevant MeSH terms:
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms
Signs and Symptoms, Respiratory
Citric Acid
Adjuvants, Anesthesia
Analgesics, Opioid
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Chelating Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sequestering Agents
Therapeutic Uses processed this record on November 30, 2015